Drug Trial Radar · NCT03406819
Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI
Last checked: Nov 20, 2026Latest source record: Jan 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,000
Planned (sponsor's estimate)
Start
Jan 7, 2018
Primary completion
Dec 31, 2018
Study completion Dec 31, 2019
Sponsor
- Lead sponsor
- The First Affiliated Hospital of Zhengzhou UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Anyang Regional Hospital; Huaihe Hospital of Henan University; The First Affiliated Hospital of Henan University of Science and Technology; Yellow River Sanmenxia hospital; The Peoples' Hospital of Jiaozuo City; Jincheng People's Hospital; The second people's Hospital of Jiyuan; Kaifeng Central Hospital; Lushan People's Hospital; Nanyang Central Hospital; The Second People's Hospital of Pingdingshan; Shenma Medical Group General Hospital; Puyang People's Hospital; Puyang Oilfield General Hospital; The First People's Hospital of Shangqiu; Yanshi People's Hospital; The First People's Hospital of Xinmi; First Affiliated Hospital of Xinjiang Medical University; Xinyang Central Hospital; People's Hospital of Zhengzhou University; Zhengzhou First People's Hospital; Chinese Academy of Medical Sciences, Fuwai Hospital; Zhengzhou Central Hospital; The 99th Central Hospital of the People's Liberation Army; Zhoukou Central Hospital; The First People's Hospital of Zhumadian; Zhumadian Central Hospital
- First posted
- Jan 23, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary percutaneous coronary intervention (PPCI) is the gold standard of treatment of ST segment elevation myocardial infarction (STEMI).Slow flow / no-reflow phenomenon following PPCI in STEMI patients has been a serious and common complication that closely related to the incidence of major adverse cardiovascular events (MACE) and affected patients' prognosis. No reflow is a multi-factorial phenomenon. And its preventive and therapeutic effects are not satisfactory. This prospective randomized controlled study aimed to compare favorable effects of Nitroprusside versus Tirofiban on the prevention of slow flow / no-reflow phenomenon during PPCI.
Conditions
- ST Segment Elevation Myocardial Infarction
- Primary Percutaneous Coronary Intervention
Interventions
Nitroprusside SodiumDrug
Intracoronary infusion 50\~100μg each time (repeated)
Tirofiban HydrochlorideDrug
Intracoronary infusion 10μg/kg for single time
Heparinized salineDrug
Intracoronary infusion 2ml for single time
Primary outcomes
What the sponsor says the trial is designed to measure.
- Coronary artery flow using thrombolysis in myocardial infarction (TIMI) flow grade after stent implantationTime frame: 1 minute after stent implantation
- Coronary artery flow using TIMI flow grade after balloon dilatationTime frame: 1 minute after balloon dilatation
- Coronary TIMI frame count after stent implantationTime frame: 1 minute after stent implantation
- Coronary TIMI frame count after balloon dilatationTime frame: 1 minute after balloon dilatation
- Slow flow / no-reflow phenomenon after stent implantationTime frame: 1 minute after stent implantation
- Slow flow / no-reflow phenomenon after balloon dilatationTime frame: 1 minute after balloon dilatation
- ECG ST-segment fall more than 50%Time frame: in 2 hours post-PCI
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
Anyang District Hospital
Anyang, Henan, China · Recruiting
The 99th Central Hospital of the People's Liberation Army
Jiaozuo, Henan, China · Recruiting
The People's Hospital of Jiaozuo
Jiaozuo, Henan, China · Recruiting
The second people's Hospital of Jiyuan
Jiyuan, Henan, China · Recruiting
Huaihe Hospital of Henan University
Kaifeng, Henan, China · Recruiting
Kaifeng Central Hospital
Kaifeng, Henan, China · Recruiting
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China · Recruiting
Lushan People's Hospital
Lushan, Henan, China · Recruiting
Nanyang City Center Hospital
Nanyang, Henan, China · Recruiting
Pingmei Shenma Medical Group General Hospital
Pingdingshan, Henan, China · Recruiting
The Second People's Hospital of Pingdingshan
Pingdingshan, Henan, China · Recruiting
Puyang Oilfield General Hospital
Puyang, Henan, China · Recruiting
Puyang People's Hospital
Puyang, Henan, China · Recruiting
Yellow River Sanmenxia hospital
Sanmenxia, Henan, China · Recruiting
The First People's Hospital of Shangqiu
Shangqiu, Henan, China · Recruiting
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China · Recruiting
Xinyang Central Hospital
Xinyang, Henan, China · Recruiting
Yanshi People's Hospital
Yanshi, Henan, China · Recruiting
Zhengzhou First People's Hospital
Zhengzhou, Henan, China · Recruiting
Zhengzhou Cardiovascular Hospital
Zhengzhou, Henan, China · Recruiting
Zhengzhou Central Hospital
Zhengzhou, Henan, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
People's Hospital of Zhengzhou
Zhengzhou, Henan, China · Recruiting
The First People's Hospital of Xinmi
Zhengzhou, Henan, China · Recruiting
Zhoukou Central Hospital
Zhoukou, Henan, China · Recruiting
The First People's Hospital of Zhumadian
Zhumadian, Henan, China · Recruiting
Zhumadian Central Hospital
Zhumadian, Henan, China · Recruiting
Jincheng People's Hospital
Jincheng, Shanxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.